Aquestive Therapeutics (AQST) Depreciation and Depletion (2018 - 2026)

Aquestive Therapeutics' Depreciation and Depletion history runs 9 years deep, the most recent figure standing at $113000.0 for Q1 2026.

• On a quarterly basis, Depreciation and Depletion fell 18.71% year-over-year to $113000.0 in Q1 2026; TTM through Mar 2026 was $522000.0, a 14.43% decrease from a year earlier, with the FY2025 full-year figure at $548000.0, down 14.38% from the prior year.
• Depreciation and Depletion slipped to $113000.0 in Q1 2026 per AQST's latest filing, from $130000.0 in the prior quarter.
• Across five years, Depreciation and Depletion topped out at $714000.0 in Q1 2022 and bottomed at $113000.0 in Q1 2026.
• The 5-year median for Depreciation and Depletion is $168000.0 (2024), against an average of $277470.6.
• Across the five-year window, Depreciation and Depletion grew 14.24% in 2023 and sank 62.6% in 2024, its largest moves.
• Year by year, Depreciation and Depletion stood at $344000.0 in 2022, then climbed by 14.24% to $393000.0 in 2023, then tumbled by 62.6% to $147000.0 in 2024, then slipped by 11.56% to $130000.0 in 2025, then dropped by 13.08% to $113000.0 in 2026.
• Per Business Quant, the three latest AQST Depreciation and Depletion figures stand at $113000.0 (Q1 2026), $130000.0 (Q4 2025), and $139000.0 (Q3 2025).